翻訳と辞書 Words near each other ・ Immunocontraception ・ Immunocore ・ Immunocytochemistry ・ Immunodeficiency ・ Immunodeficiency with hyperimmunoglobulin M ・ Immunodeficiency–centromeric instability–facial anomalies syndrome ・ Immunodermatology ・ Immunodiagnostics ・ Immunodiffusion ・ Immunodominance ・ Immunoediting ・ Immunoelectrophoresis ・ Immunoevasin ・ Immunofixation ・ Immunofluorescence ・ ImmunoGen ・ Immunogen ・ Immunogenetics ・ Immunogenetics (journal) ・ Immunogenic cell death ・ Immunogenicity ・ Immunoglobulin A ・ Immunoglobulin C1-set domain ・ Immunoglobulin C2-set domain ・ Immunoglobulin class switching ・ Immunoglobulin D ・ Immunoglobulin domain ・ Immunoglobulin E ・ Immunoglobulin G ・ Immunoglobulin heavy chain Dictionary Lists mini英和辞書 mini和英辞書 Webster 1913 Latin-English FOLDOC Wikipedia English ウィキペディア

翻訳と辞書　辞書検索 [ 開発暫定版 ] スポンサード リンク ImmunoGen ： ウィキペディア英語版 ImmunoGen ImmunoGen, Inc. () is a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts. An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity. The ADCs currently in the clinic with ImmunoGen technology all employ one of the company's maytansinoid cell-killing agents, either DM1 or DM4. DM1 attached to an antibody with ImmunoGen's thioether linker is called "emtansine" in its International Nonproprietary Name name (e.g., ado-trastuzumab emtansine). DM1 attached to an antibody with ImmunoGen's SPP linker is called "mertansine" (e.g., lorvotuzumab mertansine). DM4 attached with ImmunoGen's SPDB linker is called "ravtansine" (e.g., indatuximab ravtansine, anetumab ravtansine(BAY94-9343)), and DM4 attached with ImmunoGen's sSPDB linker is called "soravtansine". ==Collaborations & licensing== The company also selectively outlicenses limited use of its technology to other companies. Companies licensing ImmunoGen's technology include Amgen, Bayer HealthCare, Biotest, Genentech/Roche, Eli Lilly, Novartis, Sanofi, and Takeda.〔 Roche's Kadcyla (ado-trastuzumab emtansine) utilizes ImmunoGen's ADC technology. It has been approved and launched in a number of countries, including the US, where it is marketed by Genentech, a member of the Roche Group.〔http://www.gene.com/〕〔http://www.kadcyla.com/〕 In October 2015, the company disclosed that Kadcyla had failed to meets its primary endpoint in the Phase II/III GATSBY trial investigating the second line treatment of HER2-positive advanced gastric cancer.〔http://www.genengnews.com/gen-news-highlights/roche-s-kadcyla-fails-phase-ii-iii-trial-for-gastric-cancer/81251888/〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「ImmunoGen」の詳細全文を読む スポンサード リンク 翻訳と辞書 : 翻訳のためのインターネットリソース Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.